MALARIA

This study tests whether a new drug combination (SJ733 plus tafenoquine) can completely cure people with a specific type of malaria called P. vivax. About 104 adults with mild malaria will receive the treatment over 1 to 3 days. The goal is to see if the infection stays away for …

This study tests a very short, 3-day course of the drug primaquine to cure vivax malaria and prevent it from returning. Current treatments take longer, which can lead to people not finishing them. The trial will include about 1,019 people with vivax malaria who have a normal G6PD…

This study tests whether giving a half-dose of the R21/Matrix-M malaria vaccine works as well as the full dose in adults and teens aged 14 to 60. About 375 participants will be randomly assigned to receive either the full dose or one of two half-dose versions. If successful, usin…

This study tests a new device called LASER Guardian™ that releases chemicals to keep mosquitoes away from homes. Over two years, 69 villages in western Kenya will use either the LASER device, indoor insecticide spraying, or standard prevention methods. Researchers will check abou…

This study tests whether giving school children preventive malaria medicine can lower malaria cases in the entire community. Since school-aged children often carry the malaria parasite without symptoms, treating them may reduce transmission to others. The trial will involve about…

This study tests a new long-acting injection called MMV371 to see if it can safely prevent malaria. About 80 healthy people aged 12 to 50 in Rwanda will get either the study drug or a placebo. Researchers will check for side effects and measure drug levels in the body over 24 wee…

This study looks at how three malaria drugs (piperaquine, pyronaridine, and artesunate) interact when taken together. It involves 24 healthy adults in Thailand who will take the drugs in different orders and be monitored for side effects and drug levels. The goal is to understand…